Clinical trial

Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure

Opening soon · Not applicable · 1 countries · Registry ID NCT07176663

Opening soonNot applicableInterventional

What this study is about

Diabetes management presents a complex clinical scenario marked by several challenges, especially in chronic kidney failure. These include navigating potential drug interactions between oral antidiabetic therapies and other agents. Furthermore, these patients may experience various adverse drug effects, such as lactic acidosis, electrolyte abnormalities such as hypomagnesemia, fluid retention, and lipid derangements, which can further augment overall morbidity. Consequently, many patients receive insulin. However, prolonged intensive insulin therapy may be linked to several adverse outcomes, including an increased risk of hypoglycemia and weight gain. Hence, a common practice is to transition to medications commonly used other populations of patients. With their established benefits on glycemic control, cardiovascular health, renal benefits, and weight management, in conjunction with the aforementioned adverse effects associated with other oral antidiabetics agents, glucagon-like peptide-1 receptor agonists have emerged as an attractive therapeutic option for patients with kidney failure.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionObesity

Full registry criteria

Inclusion Criteria: age ≥18 years and history of diabetes or BMI over 27 Exclusion Criteria: Previous usage of similar therapy for less than 3 months owing to the inability to capture all efficacy and safety endpoints within this brief timeframe and/or nonadherence to tirzepatide therapy

Treatments and study arms

Tirzepatide

Drug

2.5 mg weekly first month and 5 mg weekly for two month

Primary outcomes

weight losskilogram of weight loss measured by same scale one and three month after injection

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Nooshin Dalili🌐 Tehran, Iran

Open map